GLP-1 obesity medications, such as Ozempic and Wegovy, play a significant role in weight management, but their effectiveness varies among individuals. Researchers at the University of Alberta are exploring the impact of energy metabolism and individual factors on the success of…
The increasing investment in longevity biotechnology aims to tackle age-related diseases and extend human lifespan. However, the complexities and potential risks associated with m…
Access to obesity drugs in the UK is divided between a slow NHS rollout of tirzepatide and a rapidly growing private market. The NHS aims to provide access over 12 years, starting…
A study published in Nature suggests that GLP-1 obesity drugs, such as semaglutide, may extend lifespan and improve health in older female mice. The research indicates that treate…
Researchers at the University of California, Berkeley, have identified an oral compound named TOFA that significantly reduces body weight in obese mice by boosting energy expendit…
Researchers at the University of Cambridge have discovered that both activating and blocking the glucose-dependent insulinotropic polypeptide receptor (GIPR) in different brain re…
The Health Products Regulatory Authority (HPRA) has confirmed over 1,500 reports of suspected adverse reactions related to anti-obesity medications, including serious gastrointest…
A recent analysis reveals that while obesity drugs like GLP-1s can lead to significant weight loss, they often do not enhance quality of life or cardiovascular health for many pat…
A recent analysis published in the British Medical Journal scrutinizes the effectiveness of popular obesity medications like Wegovy and Mounjaro, revealing that while these drugs…
Beauty industry leaders are ramping up efforts to develop treatments specifically designed for those experiencing facial volume loss, promising to redefine the standards of beauty…